Androgen Deprivation Therapy Not Found to Increase Risk of Dementia, Alzheimer’s

Androgen Deprivation Therapy Not Found to Increase Risk of Dementia, Alzheimer’s
Prostate cancer patients receiving androgen deprivation therapy (ADT) are not at increased risk of dementia or Alzheimer’s disease, according to a study in the Journal of Clinical Oncology. ADT involves depriving patients of androgen hormones such as testosterone, which are necessary for prostate cancer cells to grow. It is the preferred treatment for patients with advanced disease. Concerns have been raised about whether ADT increases patients' risk of developing cognitive anomalies and Alzheimer’s disease. "Cognitive impairment is a known side effect of declining testosterone, in general, so it is naturally of concern with ADT," said Laurent Azoulay, PhD, lead researcher of the study, “
Subscribe or to access all post and page content.